A Message from the President

Masayo TadaMasayo TadaRepresentative Director,
President and CEO

Sumitomo Dainippon Pharma Co., Ltd., operates every day to achieve its corporate mission "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide". By pouring all our efforts into the research and development of new drugs, we aim to provide innovative and effective pharmaceutical solutions to people not only in Japan but also around the world in order to realize our corporate mission.

With our acquisition of Sepracor Inc. (current Sunovion Pharmaceuticals Inc.) in 2009, we have established our own sales and marketing infrastructure in the U.S. The globalization of our operations has progressed significantly by the 2011 launch of Latuda®, a key product in our global business strategy. We were also successful in gaining a strong foothold in the oncology area through the 2012 acquisition of Boston Biomedical Inc., a U.S. biotechnology venture company.

In our Third Mid-term Business Plan that began in 2013, our corporate vision is two-fold: "Aspire to be a globally active R&D-based company" and "Contribute to medical care through leading-edge technologies." For the realization of this vision, we are redoubling efforts to promote innovations. In addition to the focused research and development areas of Psychiatry & Neurology and Oncology, we are channeling our R&D energies also into two new fields: diseases for which no approved drugs exist as well as Regenerative Medicine/Cell Therapy.

Constantly aware of our responsibility to you and all our stakeholders from patients, their families and medical caregivers to our shareholders, employees and the communities where we work, we pledge our unflagging efforts to earn and maintain your trust in us. On behalf of all us at Sumitomo Dainippon Pharma, I would like to ask for your continued support and encouragement.